Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | NLN | Q9BYT8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL713213 | 0.90 | LTA4H (0.62) | LTA4HCYP3A4SLC7A5NLN | |
| SCHEMBL13061496 | 0.90 | LTA4H (0.62) | LTA4HCYP3A4SLC7A5NLN | |
| Hydrochloric Acid SCHEMBL27320108 | 0.89 | LTA4H (0.61) | LTA4HCYP3A4SLC7A5 | |
| SCHEMBL3626018 | 0.83 | CYP3A4 (0.58) | LTA4HCYP3A4SLC7A5NLN | |
| SCHEMBL1007042 | 0.83 | CYP3A4 (0.61) | LTA4HCYP3A4SLC7A5NLN | |
| SCHEMBL28231837 | 0.80 | CYP3A4 (0.57) | LTA4HCYP3A4SLC7A5NLN | |
| SCHEMBL6114085 | 0.79 | CYP3A4 (0.62) | LTA4HCYP3A4SLC7A5NLN | |
| Phenylalanine SCHEMBL28074950 | 0.78 | SLC7A5 (0.80) | LTA4HCYP3A4SLC7A5NLN | |
| SCHEMBL27492929 | 0.78 | CYP3A4 (0.58) | LTA4HCYP3A4SLC7A5NLN | |
| SCHEMBL388562 | 0.77 | CYP3A4 (0.73) | CYP3A4SLC7A5HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040204348-A1 | Cyclic peptide ligands that target urokinase plasminogen activator receptor | THE ANGSTROM PHARMACEUTICALS, INC. | 2004-10-14 | — | — | US | disclosed |
| EP-1144604-A1 | CYCLIC PEPTIDE LIGANDS THAT TARGET UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR, THEIR PHARMACEUTICAL COMPOSITIONS AND USE | Angstrom Pharmaceuticals, inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000026353-A1 | CYCLIC PEPTIDE LIGANDS THAT TARGET UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR, THEIR PHARMACEUTICAL COMPOSITIONS AND USE | ANGSTROM PHARMACEUTICALS, INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| EP-0941235-A1 | CYCLIC PEPTIDES THAT BIND TO UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR | Angstrom Pharmaceuticals, inc. (US) | 1999-09-15 | — | — | EP | disclosed |
| WO-1998021230-A1 | CYCLIC PEPTIDES THAT BIND TO UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR | ANGSTROM PHARMACEUTICALS, INC. (US) | 1998-05-22 | — | — | WO | disclosed |
| CN-1109780-A | Sustained-release preparation of anti-endothelin substance | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-10-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204348-A1 | Cyclic peptide ligands that target urokinase plasminogen activator receptor | PLAUR, PLAU, PLG | LTA4H 1929/4885CYP3A4 4707/4885SLC7A5 2719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.